Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Testosterone
Drug ID BADD_D02170
Description Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.[A187114,L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone was isolated from samples and also synthesized in 1935.[A186943]
Indications and Usage Testosterone is indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995]
Marketing Status approved; investigational
ATC Code G03BA03
DrugBank ID DB00624
KEGG ID D00075
MeSH ID D013739
PubChem ID 6013
TTD Drug ID D06XMU
NDC Product Code 0832-1120; 65089-0050; 43598-304; 49884-418; 63629-8455; 63629-9310; 0591-2925; 38779-2936; 43647-568; 43742-1436; 73774-014; 76003-1083; 43742-1242; 0245-0871; 62332-552; 70700-112; 76420-685; 76420-687; 76420-699; 24979-130; 45802-610; 0051-8462; 64380-151; 68180-943; 69097-363; 0591-2363; 0603-7831; 0009-5020; 44132-006; 49452-7658; 64025-0010; 45802-281; 0245-0872; 0023-5992; 63629-2125; 64380-152; 66887-001; 0591-2114; 0591-2924; 0591-2926; 0591-3216; 0832-1121; 51927-0267; 70492-002; 76420-684; 0009-0074; 12875-8248; 22552-0009; 49452-7652; 60592-721; 60870-0251; 16714-967; 17139-562; 63629-2124; 68180-941; 44132-008; 48087-0113; 51552-0029; 42667-5511; 63481-183; 63629-2352; 69238-1013; 0591-3217; 0591-3524; 38779-0163; 38779-2598; 82393-113; 24979-078; 45802-366; 66887-004; 51552-0564; 62991-2150; 76420-686; 16714-969; 45802-754; 49884-510; 62332-488; 69339-158; 0591-2921; 49452-7657; 16714-968; 0023-5990
UNII 3XMK78S47O
Synonyms Testosterone | 17-beta-Hydroxy-4-Androsten-3-one | 17 beta Hydroxy 4 Androsten 3 one | Androtop | Histerone | Sterotate | Sustanon | Androderm | Testoderm | Testolin | Testopel | Testosterone Sulfate | AndroGel | 8-Isotestosterone | 8 Isotestosterone | 17-beta-Hydroxy-8 alpha-4-Androsten-3-one | 17 beta Hydroxy 8 alpha 4 Androsten 3 one | Andropatch | Testim
Chemical Information
Molecular Formula C19H28O2
CAS Registry Number 58-22-0
SMILES CC12CCC3C(C1CCC2O)CCC4=CC(=O)CCC34C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Loss of consciousness17.02.04.004---
Lung disorder22.02.07.0010.002272%-
Malabsorption07.17.01.001; 14.02.01.0040.000463%
Malaise08.01.01.003--
Male orgasmic disorder19.08.01.006; 21.03.02.019---
Menopausal symptoms21.02.02.002---
Menstruation irregular05.05.01.008; 21.01.01.005--
Micturition urgency20.02.02.006--
Migraine17.14.02.001; 24.03.05.003---
Mitral valve incompetence02.07.01.0020.000136%-
Mood swings19.04.03.001---
Mouth ulceration07.05.06.004---
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Myocardial infarction02.02.02.007; 24.04.04.0090.096243%
Myocardial ischaemia02.02.02.008; 24.04.04.0100.001000%-
Nasal congestion22.04.04.001--
Nasal dryness22.04.03.0020.000618%-
Nasal oedema22.04.03.012---
Nasopharyngitis11.01.13.002; 22.07.03.002---
Nausea07.01.07.001--
Neoplasm16.16.02.001---
Neoplasm malignant16.16.01.001---
Neoplasm prostate16.25.02.001; 21.04.02.003---
Nephrolithiasis20.04.01.002--
Nervous system disorder17.02.10.0010.000954%-
Nervousness19.06.02.003---
Nipple disorder21.05.04.006--
Nipple pain21.05.05.0090.000927%-
Nocturia20.02.03.0010.000245%-
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 19 Pages